Study: NCT02915016

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA-HIV-PT123 vaccine
Description: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA-HIV-PT123 vaccine
Description: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA-HIV-PT123 vaccine
Description: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA-HIV-PT123 vaccine
Description: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA-HIV-PT123 vaccine
Description: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA-HIV-PT123 vaccine
Description: Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent Subtype C gp120/MF59 vaccine
Description: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent Subtype C gp120/MF59 vaccine
Description: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent Subtype C gp120/AS01B vaccine
Description: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.~Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent Subtype C gp120/AS01B vaccine
Description: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.~Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent Subtype C gp120/AS01B vaccine
Description: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.~Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent Subtype C gp120/AS01B vaccine
Description: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.~Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent Subtype C gp120/AS01B vaccine
Description: Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.~Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.